Shortly before the US patent was granted, the Fife-based company similarly saw its UK patent application granted in June. Credit: Shutterstock / Mark Van Scyoc

Biocaptiva, has announced that it has been granted its first US patent that covers anew liquid biopsy technology designed to efficiently capture cell-free DNA (cfDNA) directly from blood.

Intended as a new method of early disease detection and monitoring, as well as advancing personalised medicine, the system has been patented under the name msX, with the company confirming that this patent will now set the stage for its current and future product pipeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The US Patent and Trademark Office (USPTO), entitled ‘Methods for Isolating DNA from a Blood Sample’ (US-20240294898-A1) means that in the US the Scottish company will have exclusive rights over the production and marketing of the technology, covering both in-vivo and ex-vivo applications until the patent expires or is invalidated by a competitor via litigation.

Jeremy Wheeler, CEO of Biocaptiva, said: “This US patent grant is a crucial achievement. It not only secures our intellectual property but also underscores the extensive potential of our technology, which we’ve been developing since spinning out of the University of Edinburgh in 2020. What began as a focused research project and a single medical device has evolved into a comprehensive platform with far-reaching implications for liquid biopsy and the broader biomedical industry.”

Shortly before the US patent was granted, the Fife-based company similarly saw its UK patent application granted in June.

See Also:

The technology, which began life at the University of Edinburgh can capture nucleic acids, particularly cfDNA, directly from biological fluids such as blood, and plasma in greater quantities than is currently possible with traditional methods without the need to use a centrifuge. The company says that samples taken using its now proprietary system can be stored at room temperature for up to 90 days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Now the companyplans to commercialise the technology across a range of indications from the earlier detection of cancer to enhancing biomedical research and creating more personalised medicines for patients.

Elsewhere in the field of personalised medicine and DNA analysis, Exact Sciences has accepted the first patient in a trial of its multi-cancer early detection trial. Meanwhile, data published in the Cancer Cell journal has found a new liquid biopsy method that has the potential to monitor disease evolution in patients with prostate cancer.